Latest Conference Content

Susan Cantrell, CEO of the Academy of Managed Care Pharmacy, shares exclusive insights on key themes that will be discussed at this year's Nexus conference.

Dedicated COPD respiratory therapists can improve inhaler use, ensure adherence, and bridge care transitions, explained Megan Dulohery Scrodin, MD.

Meta-analyses presented at the CHEST 2025 Annual Meeting find that combinations that include amivantamab and nivolumab improved overall and progression-free survival in non–small cell lung cancer (NSCLC).

Assessing all available nonhormonal and hormonal therapies for vasomotor symptoms helps empower women to make informed decisions, said Lee Shulman, MD.

Digitized behavioral cough suppression therapy is a safe, highly effective, and accessible alternative to drugs for chronic cough, said Laurie Slovarp, PhD.

The efficacy of GLP-1 inhibitors in weight loss has introduced them as a means of also addressing obstructive sleep apnea in sleep medicine.

Experts also explained how hormone therapy can benefit women managing chronic conditions such as diabetes and hypertension on top of their menopause.

A session held during the CHEST 2025 Annual Meeting focused on the North American guidelines for treating bronchiectasis.

CT scans can play a role not just in diagnosing but also in monitoring non–cystic fibrosis bronchiectasis management, explained James D. Chalmers, MD.

Researchers will present new findings on how menopause affects cardiovascular, brain, metabolic, and digestive health.

Perioperative enfortumab vedotin plus pembrolizumab demonstrated significant results in a population that represents roughly half of all patients with MIBC, explained Christof Vulsteke, MD, PhD.

Inhaled corticosteroids pose long-term risks in COPD management, prompting careful screening and potential de-escalation strategies, said Sara Assaf, MD.

Counseling patients with obstructive sleep apnea on using GLP-1s effectively prior to starting treatment can help ensure adherence, said Matthew Biszewski, PharmD.

Balazs Halmos, MD, of Montefiore Albert Einstein Cancer Center, discussed the potential impact of subcutaneous amivantamab EGFR-mutated NSCLC.

New findings reveal that combining Pluvicto with standard therapies significantly improves outcomes for patients with prostate cancer, enhancing quality of life.

Experts at the European Society for Medical Oncology Congress meeting in Berlin, Germany, explore rising cancer rates in young adults, focusing on survivorship challenges and the role of lifestyle interventions in care.

Despite advances, Arielle Kauvar, MD, calls for more research on laser and energy-based devices for patients with skin of color.

Phenotyping patients can help to identify potential heart failure with preserved ejection fraction (HFpEF) as well as improve patient outcomes.

A mini oral session at ESMO of targeted therapy in non-small cell lung cancer included treatments that showed effectiveness in brain metastases.

Intensivists gathered at the CHEST 2025 Annual Meeting to discuss how climate change is affecting and will affect their practice of treating pulmonary conditions.

Rebecca Dent, MD, MSc, of the National Cancer Center in Singapore, gives insights on the use of antibody-drug conjugates (ADCs) in early breast cancer treatment.

Results from the ASPEN trial also show that brensocatib displayed several benefits when used in patients with bronchiectasis, including a reduction in symptom burden.

New KEYNOTE-B96 data add to previous results showing progression-free survival (PFS) and overall survival (OS) improvements vs placebo.

Stephen Freedland, MD, of Cedars-Sinai, discussed enzalutamide and leuprolide's potential to improve overall survival without sacrificing quality of life in prostate cancer.

Experts at ESMO Congress highlighted the urgent need for open discussions on sexual health post cancer treatment, emphasizing its impact on quality of life.

Combination therapy with enfortumab vedotin and pembrolizumab significantly reduces progression and mortality risk of muscle invasive bladder cancer in first-line treatment.

Colorblind energy devices and long-wavelength lasers are safest for darker skin, says Ariella Kauvar, MD, with a thorough patient history and physical exam key to preventing complications.

Adjuvant abemaciclib (Verzenio; Eli Lilly) plus endocrine therapy prolonged survival in high-risk HR-positive, HER2-negative early-stage breast cancer.